Literature DB >> 18383428

The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people.

Emil Loldrup Fosbøl1, Gunnar H Gislason, Søren Jacobsen, Steen Z Abildstrom, Morten Lock Hansen, Tina Ken Schramm, Fredrik Folke, Rikke Sørensen, Jeppe N Rasmussen, Lars Køber, Mette Madsen, Christian Torp-Pedersen.   

Abstract

PURPOSE: To describe the nationwide pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) in the Danish population.
METHODS: All Danish citizens aged 10 or above 1 January 1997 were included in the study. The national prescription registry was used to identify all claimed prescriptions for NSAIDs by the cohort until 2005. By individual-level-linkage of nationwide registries, information was acquired concerning hospitalizations, comorbidity, concomitant pharmacotherapy and socioeconomic factors.
RESULTS: The population consisted of 4,614,807 individuals, of which 2,663,706 (57.8%) claimed at least one prescription for NSAID from 1997 to 2005. Ibuprofen and diclofenac were the most frequently used non-selective NSAIDs, whereas rofecoxib and celecoxib were the most frequently used selective cyclooxygenase-2 (COX-2) inhibitors. The usage was similar across all age groups. Female sex and increasing age was associated with increased use of NSAID. Factors predicting extensive NSAID use were: rheumatic disease (odds ratio (OR) = 1.79, 95% confidence interval (CI): 1.69-1.90), gout agents (allopurinol) (OR = 2.54, CI: 2.44-2.64) and other pain medication (OR = 3.27, CI: 3.23-3.31). NSAIDs were most often prescribed for use for one distinct treatment interval and for a short period (overall inter-quartile range [IQR]: 9-66 days). High doses were used in a relatively large proportion of the population (8.9% for etodolac to 19.5% for celecoxib) and 54,373 (2.0%) claimed prescriptions for more than one NSAID at the same time.
CONCLUSION: NSAIDs were commonly used in the Danish population. Since NSAIDs have been associated with increased cardiovascular risk, further research on the overall risk associated with these drugs on a national scale is needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383428     DOI: 10.1002/pds.1592

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  35 in total

1.  High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study.

Authors:  Rickard Ljung; Yunxia Lu; Jesper Lagergren
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database.

Authors:  Philippe Latry; Mathieu Molimard; Bernard Bégaud; Karin Martin-Latry
Journal:  Eur J Clin Pharmacol       Date:  2010-04-29       Impact factor: 2.953

3.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

4.  Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.

Authors:  Mai Duong; Francesco Salvo; Antoine Pariente; Abdelilah Abouelfath; Regis Lassalle; Cecile Droz; Patrick Blin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

5.  A microdialysis study of topically applied diclofenac to healthy humans: Passive versus iontophoretic delivery.

Authors:  Birgit Falk Riecke; Else Marie Bartels; Søren Torp-Pedersen; Søren Ribel-Madsen; Henning Bliddal; Bente Danneskiold-Samsøe; Lars Arendt-Nielsen
Journal:  Results Pharma Sci       Date:  2011-11-04

Review 6.  Sex differences in innate immunity and its impact on opioid pharmacology.

Authors:  Hillary H Doyle; Anne Z Murphy
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

Review 7.  Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Authors:  Nicholas Moore
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

8.  Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study.

Authors:  Jean-Pascal Fournier; Agnès Sommet; Robert Bourrel; Stéphane Oustric; Atul Pathak; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

9.  Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.

Authors:  Deirdre P Cronin-Fenton; Lars Pedersen; Timothy L Lash; Søren Friis; John A Baron; Henrik T Sørensen
Journal:  Breast Cancer Res       Date:  2010-03-01       Impact factor: 6.466

10.  COX-2 inhibitor and non-selective NSAID use in those at increased risk of NSAID-related adverse events: a retrospective database study.

Authors:  Svetla Gadzhanova; Jenni Ilomäki; Elizabeth E Roughead
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.